跳至主要内容
临床试验/NCT00976872
NCT00976872已完成不适用

Supplementation of Omega-3 Fatty Acid Complex to Routine Statin Treatment Decreases Patients' Day-time Blood Pressure, Improves Inflammatory Status and Prohibits Platelet Aggregation

Assaf-Harofeh Medical Center0 个研究点目标入组 52 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
52
主要终点
augmentation index

研究概览

简要总结

Recent evidences showed beneficial effects of omega-3 fatty acids on cardiovascular morbidity and mortality.

Regular Omega-3 fatty acid consumption reduces cardiovascular mortality, ischemic heart disease and stroke mortality. There is probably no single mechanism of action that explains this beneficial effect; but possible mechanisms include reduce susceptibility of the heart to ventricular arrhythmia, antithrombogenic effect, reduce triglyceride level, promotion of nitric oxide-induced endothelial relaxation, and retard growth of atherosclerotic plaque.

The combination of satins and omega3 was proved to be better the any of the drugs alone in several studies.

The purpose of the study is to investigate several possible mechanisms that may explain the add on beneficial effect of omega-3 in hypercholesterolemic patients already treated with satins.

详细描述

Cardiovascular disease is a leading cause of death in the western world. HMG-co A Reductase (statins) stands in the first line of treatment of cardiovascular disease because of their direct effect on LDL and their pleotrophic effect (mainly anti-inflammatory).

Recent evidences showed beneficial effects of omega-3 fatty acids on cardiovascular morbidity and mortality

Regular Omega-3 fatty acid consumption reduces cardiovascular mortality , , ischemic heart disease and stroke mortality. There is probably no single mechanism of action that explains this beneficial effect; but possible mechanisms include reduce susceptibility of the heart to ventricular arrhythmia, antithrombogenic effect , reduce triglyceride level , promotion of nitric oxide-induced endothelial relaxation , , and retard growth of atherosclerotic plaque.

Statins have a proven survival benefit in patients with hypercholesterolemia by preventing both primary and secondary cardiovascular events . Statins also has beneficial effect on lipid profile (mainly LDL and less triglycerides), they reduce plaque growth and improves endothelial function.

Many studies have demonstrated the additive effect of the combination of statins and omega-3 fatty acids on lipid profile, as well as additive effect on inflammatory markers (IL-6 and CRP).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
30 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • dyslipidemia controlled (LDL < 130)
  • statin treatment
  • triglycerides < 200
  • informed consent

排除标准

  • thrombocytopenia or bleeding tendency
  • uncontrolled diabetes mellitus
  • uncontrolled hypertension (systolic > 160 or diastolic > 100)
  • omega 3 pretreatment
  • recent acute coronary syndrome or cerebrovascular event (less than 3 months)

研究组 & 干预措施

omega-3

Active Comparator

omega-3: 2 pills of Omega"950"®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA

干预措施: omega-3 (Drug)

placebo

Placebo Comparator

hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil

干预措施: placebo (Drug)

结局指标

主要结局

augmentation index

时间窗: 0, 3 weeks, 6 weeks, 20 weeks

Each patient was seated in a quiet room, blood pressure was measured. Radial artery pressure waveform was sampled with a Millar tonometer (SPC-301, Millar Instruments) and calibrated to the average blood pressure. Waveforms were then processed using the specific software (SphygmoCor, version 7, AtCor). Integral system software was used for calculation of the averaged radial artery waveform and derivation of the corresponding central aortic pressure waveform, using a previously validated generalized transfer function.

次要结局

  • blood pressure (24 hours monitor)(0, or 3 weeks, 6 weeks, 20 weeks)
  • platelet function(0, 3 weeks, 6 weeks, 20 weeks)
  • Isoprostane(0, 3 weeks, 6 weeks, 20 weeks)
  • PAI-1, TNF-alpha, IL6(0, 3,6 and 20 weeks)

研究者

申办方类型
Other Gov

相似试验

Omega 3 Action on Cardiovascular Risk Factors in... | 临床试验